Company: CDLX
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001666071-25-000159
Chunk: 100

Company: Cardlytics, Inc.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 1
Chunk 100
---
$(173,715)Net Loss per share, basic and diluted$(1.36)$(2.90)$(1.81)$(3.66)Weighted-average common shares outstanding, basic and diluted53,493 50,028 52,708 47,469 

See notes to the condensed consolidated financial statements4

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS (UNAUDITED)

(Amounts in thousands)

 Three Months EndedSeptember 30,Nine Months EndedSeptember 30, 2025202420252024Net Loss$(72,673)$(145,182)$(95,238)$(173,715)Other Comprehensive Income (Loss):Foreign currency translation adjustments1,590 (4,451)(5,639)(3,965)Total Comprehensive Loss$(71,083)$(149,633)$(100,877)$(177,680)

See notes to the condensed consolidated financial statements5

CARDLYTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (UNAUDITED)

(Amounts in thousands)

Nine Months Ended September 30, 2025:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensive Income (Loss)AccumulatedDeficitTotal Common Stock SharesAmountBalance – December 31, 202451,257 $10 $1,366,958 $3,601 $(1,300,576)$69,993 Stock-based compensation— — 25,733 — — 25,733 Settlement of restricted stock2,286 — — — — — Issuance of common stock pursuant to the 2018 ESPP (as defined below)263 — 447 — — 447 Other comprehensive loss— — — (5,639)— (5,639)Net Loss— — — — (95,238)(95,238)Balance – September 30, 202553,806 $10 $1,393,138 $(2,038)$(1,395,814)$(4,704)

Three Months Ended September 30, 2025:

  AdditionalPaid-InCapitalAccumulatedOtherComprehensive LossAccumulatedDeficitTotal Common Stock SharesAmountBalance – June 30, 202552,